Clinical trial
Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells…
NCT00102128 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00102128 |
|---|---|
| Title | Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack. |
| Official title | Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ischemic Heart Failure, Ischemic Heart Disease, Ischemic Cardiomyopathy |
| Intervention type | Drug |
| Interventions | Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation) |
| Start date | Nov 1, 2002 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Jan 24, 2005 |
| Last update posted | May 22, 2015 |
| Countries | Belgium, France, Germany, Italy, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: